Olema Pharmaceuticals (NASDAQ: OLMA) insider transactions
In the twelve months to 10 November 2026, executives and directors of Olema Pharmaceuticals reported 25 open-market sales of 880,501 shares ($24.7m) and 0 open-market purchases, by 6 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 24 July 2026 | Harmon Cyrus | Director | Open-market sale | −12,500 | $11.71 | 702,770 | Form 4 |
| 23 July 2026 | Harmon Cyrus | Director | Open-market sale | −12,500 | $11.58 | 715,270 | Form 4 |
| 4 March 2026 | Mitchell Shawnte | Chief Legal Officer | Option exercise | +25,000 | $4.37 | 25,000 | Form 4 |
| 4 March 2026 | Mitchell Shawnte | Chief Legal Officer | Open-market sale | −24,767 | $24.25 | 233 | Form 4 |
| 4 March 2026 | Mitchell Shawnte | Chief Legal Officer | Open-market sale | −233 | $24.69 | 0 | Form 4 |
| 3 March 2026 | Mitchell Shawnte | Chief Legal Officer | Option exercise | +15,000 | $4.37 | 15,000 | Form 4 |
| 3 March 2026 | Mitchell Shawnte | Chief Legal Officer | Open-market sale | −15,000 | $23.01 | 0 | Form 4 |
| 2 February 2026 | Austin Sasha Lu | VP of Finance and Controller | Grant or award | +11,700 | — | 16,188 | Form 4 |
| 20 January 2026 | Harmon Cyrus | Director | Open-market sale | −10,000 | $26.88 | 727,770 | Form 4 |
| 15 January 2026 | Kovacs Shane William Charles | Ch. Operating & Financial Off. | Open-market sale | −100,000 | $28.73 | 139,727 | Form 4 |
| 14 January 2026 | Harmon Cyrus | Director | Open-market sale | −3,489 | $29.12 | 737,770 | Form 4 |
| 14 January 2026 | Myles David C. | Ch. Discov. & Non-clin Dev Off | Option exercise | +50,000 | $4.87 | 592,761 | Form 4 |
| 14 January 2026 | Myles David C. | Ch. Discov. & Non-clin Dev Off | Open-market sale | −14,997 | $28.60 | 577,764 | Form 4 |
| 14 January 2026 | Myles David C. | Ch. Discov. & Non-clin Dev Off | Open-market sale | −35,003 | $28.99 | 542,761 | Form 4 |
| 13 January 2026 | Kovacs Shane William Charles | Ch. Operating & Financial Off. | Open-market sale | −3,822 | $28.01 | 239,727 | Form 4 |
| 13 January 2026 | Myles David C. | Ch. Discov. & Non-clin Dev Off | Option exercise | +50,000 | $4.87 | 592,761 | Form 4 |
| 13 January 2026 | Myles David C. | Ch. Discov. & Non-clin Dev Off | Open-market sale | −49,800 | $27.60 | 542,961 | Form 4 |
| 13 January 2026 | Myles David C. | Ch. Discov. & Non-clin Dev Off | Open-market sale | −200 | $28.49 | 542,761 | Form 4 |
| 12 January 2026 | Myles David C. | Ch. Discov. & Non-clin Dev Off | Open-market sale | −10,000 | $28.34 | 144,846 | Form 4 |
| 26 December 2025 | Bohen Sean | President and CEO | Gift | −8,500 | — | 237,650 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Olema Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.